Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

That study, based on an older return calculation method that has since been widely replicated, highlighted the strong ...

Pfizer’s stock has inched up lately, but analysts predict a possible 25% rise based on a $28.52 average price target. While ...

Pfizer has received a “Moderate Buy” consensus from fifteen analysts, signaling cautious optimism rather than fanfare. One ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Iris Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.